https://www.oncologynurseadvisor.com Fri, 01 Mar 2024 17:55:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/cancer-black-box-warning-cart-therapy-unlikely-clinical-treatment-risk/ Fri, 01 Mar 2024 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=117008 The black box warnings are unlikely to deter clinicians from prescribing CAR-T therapies, largely because these patients frequently have few other options. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/perioperative-nivolumab-improves-efs-in-nsclc-2/ Tue, 13 Feb 2024 14:15:00 +0000 https://www.oncologynurseadvisor.com/?p=113595 https://www.oncologynurseadvisor.com/home/departments/radiation-and-your-patient/radiotherapy-salivary-glands-hypo-salivation-patients-treatment-risk/ Fri, 12 Jan 2024 15:55:00 +0000 https://www.oncologynurseadvisor.com/?p=116006 This review discusses the causes of radiotherapy-induced damage to salivary glands, preventive measures, and treatments in patients who received radiation in the treatment of head and neck cancers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/why-bladder-cancer-patients-not-receiving-immunotherapy/ Tue, 02 Jan 2024 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=115192 Age, sex, insurance status, and other factors were associated with receipt of immunotherapy in a study of patients with metastatic bladder cancer.]]> https://www.oncologynurseadvisor.com/reports/wearable-device-cytokine-release-crs-cart-therapy-myeloma-treatment/ Thu, 21 Dec 2023 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=115130 Researchers investigated the feasibility of using a wearable device to monitor patients with RRMM for CRS after undergoing CAR-T therapy, compared with standard-of-care nurse-recorded monitoring. ]]> https://www.oncologynurseadvisor.com/reports/financial-toxicity-myeloma-navigation-may-help-find-aid-treatment-risk/ Tue, 19 Dec 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=115024 A pilot project at a Philadelphia cancer center sought to improve awareness of financial assistance resources for patients with multiple myeloma.]]> https://www.oncologynurseadvisor.com/home/hot-topics/side-effect-management/acute-leukemia-asparaginase-hypersensitive-immune-reaction-key-tool/ Thu, 14 Dec 2023 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114951 L-asparaginase is a powerful tool in treating acute lymphoblastic leukemia but oncology nurses must be on the look-out for immune hypersensitivity reactions and other serious toxicities, monitoring patients and managing these reactions when they occur.]]> https://www.oncologynurseadvisor.com/reports/cart-therapy-bcell-lymphoma-clinical-frailty-score-treatment-risk/ Wed, 13 Dec 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114919 Researchers explored whether clinical frailty assessment impacts outcomes of CAR-T therapy and whether changes in frailty before and after therapy affect outcomes.]]> https://www.oncologynurseadvisor.com/reports/graft-host-disease-post-transplant-cyclophosphamide-protect-gvhd/ Tue, 12 Dec 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114859 Tacrolimus/methotrexate (Tac/MTX) is standard prophylaxis against GVHD in patients undergoing HSCT.]]> https://www.oncologynurseadvisor.com/reports/acute-leukemia-icans-crs-brexucel-high-real-world-rates-brexucabtagene/ Tue, 12 Dec 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114861 Researchers report on the rates of CRS and ICANS in patients with relapsed/refractory B-ALL who are treated with brexucabtagene autoleucel.]]>